Actionable news
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

These Analysts Remain Bearish on Valeant Pharmaceuticals Intl Inc (VRX), Neutral on Gilead Sciences, Inc. (GILD)

Healthcare analysts are weighing in today on healthcare giants Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD). While one analyst remains bearish on Valeant ahead of upcoming FDA advisory committee of Brodalumab for psoriasis, the other keeps his neutral stance on Gilead following the release of new HIV treatment guidelines. Let’s take a closer look:

Valeant Pharmaceuticals Intl Inc

In a research report issued Friday, Mizuho Securities analyst Irina Rivkind Koffler reiterated an Underperform rating on shares of Valeant with a price target of $11.00, after the FDA released briefing documents ahead of the Ophthalmic Drugs Advisory Committee meeting to discuss approval of Valeant’s Brodalumab for psoriasis.

Koffler wrote, “FDA’s division of Epidemiology calculated that Brodalumab has a rate of suicide that is 3-4x higher than that seen in clinical trials for other biologics. FDA will therefore consider a number of options and internal recommendations, ranging from issuing a complete response letter (asking for longer follow up of patients in a clinical trial)...